Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 18 to 65 years of age~* History of Type 2 Diabetes Mellitus for at least 3 months prior to Screening, with HgbA1c values of 6.5 to 10.5% and C-peptide ≥1.0 ng/mL~* Body mass index (BMI) ≤45 kg/sq m~* Willing and able to self-monitor blood glucose~* Able to provide written informed consent~Exclusion Criteria:~* History of Type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketotic syndrome, or diabetes resulting from pancreatic disorder or secondary diabetes~* Current use of any blood glucose lowering agent other than metformin~* History of renal disease or clinically significant abnormal kidney function tests at Screening or Day -2~* Presence of active hepatic disease or clinically significant abnormal liver function tests at Screening or Day -2~* History of myocardial infarction, severe/unstable angina, or coronary revascularization procedure within 6 months of Day -2~* History of clinically significant cardiac arrhythmias within 1 year of Day -2~* Congestive heart failure and/or New York Heart Association (NYHA) class III or IV symptoms of heart failure~* Subjects with uncontrolled Stage 3 hypertension~* History of 2 or more emergency room visits, doctor's visits, or hospitalizations due to hypoglycemia within 6 months of Day -2~* History of alcohol or drug abuse within 12 months of Screening~* History of bowel resection \> 20 cm, any malabsorptive disorder, severe gastroparesis, and GI procedure for the purpose of weight loss that would slow gastric emptying~* History of HIV or hepatitis C~* Major surgery within 3 months of Day -2 or any planned surgery during the study~* History of any active infection within 2 weeks of Day -2~* History of pancreatitis~* History of any malignancy within the last 5 years which would affect the diagnosis or assessment of LX4211 or sitagliptin~* History of any serious adverse reaction or hypersensitivity to LX4211 or sitagliptin~* Presence of any clinically significant physical, laboratory, or ECG findings or any concurrent condition at Screening that may interfere with the study in the opinion of the investigator~* Triglycerides \> 1000 mg/dL at Screening or Day -2~* Donation or loss of \>400 mL of blood or blood product within 8 weeks prior to Day -2~* Use of any tobacco product for the duration of study participation~* Use of corticosteroids within 2 weeks of Day 1~* Use of digoxin or warfarin within 2 weeks prior to Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: EXPERIMENTAL): None
- Treatment C (Type: EXPERIMENTAL): None
- Treatment B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).